

Dario Cattaneo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7905150/dario-cattaneo-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

157
papers

4,080
citations

30
h-index

60
g-index

159
ext. papers

4,624
ext. citations

5.1
avg. IF

5.31
L-index

#	Paper	IF	Citations
157	Delayed graft function in kidney transplantation. <i>Lancet, The</i> , 2004 , 364, 1814-27	40	704
156	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 341-58	6.9	226
155	Regulatory T cells and T cell depletion: role of immunosuppressive drugs. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1007-18	12.7	202
154	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , 2002 , 62, 1060-7	9.9	181
153	Hepatitis C infection and chronic renal diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 207-20	6.9	152
152	How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2898-908	12.7	131
151	Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2276-2278	11.6	114
150	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011 , 25, 47-57	3.3	89
149	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002 , 61, 1635-45	9.9	88
148	Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. <i>Transplantation</i> , 2007 , 84, 956-64	1.8	84
147	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. <i>Pharmacogenomics</i> , 2007 , 8, 1127-41	2.6	82
146	Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013 , 41, 586-9	14.3	75
145	Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. <i>Aids</i> , 2007 , 21, 2409-15	3.5	71
144	Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 827-38	6.2	66
143	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001 , 15, 402-9	3.8	66
142	ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1404-15	12.7	56
141	Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. <i>Circulation</i> , 2003 , 107, 586-92	16.7	54

140	Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. <i>American Journal of Transplantation</i> , 2004 , 4, 1345-51	8.7	53
139	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. <i>Clinical Chemistry</i> , 2001 , 47, 1679-1687	5.5	52
138	From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. <i>American Journal of Transplantation</i> , 2004 , 4, 299-310	8.7	49
137	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 460-4	5.1	48
136	Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 1147-53	6.9	47
135	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. <i>Pharmacological Research</i> , 2020 , 157, 104826	10.2	40
134	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 533-44	5.5	39
133	Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. <i>Pharmacological Research</i> , 2012 , 65, 472-9	10.2	38
132	A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. <i>Pharmacological Research</i> , 2011 , 64, 210-7	10.2	35
131	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 782-6	3.2	34
130	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 435-44	5.9	33
129	Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. <i>Health Policy</i> , 2012 , 104, 247-52	3.2	32
128	Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. <i>British Journal of Pharmacology</i> , 2010 , 160, 1550-60	8.6	32
127	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 816, 99-105	3.2	30
126	Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. <i>PLoS ONE</i> , 2013 , 8, e80242	3.7	30
125	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- α in primary CNS lymphoma. <i>Blood</i> , 2019 , 134, 252-262	2.2	29
124	Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. <i>Clinica Chimica Acta</i> , 2006 , 364, 354-8	6.2	29
123	Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 6132-5	5.9	27

122	Does lopinavir really inhibit SARS-CoV-2?. <i>Pharmacological Research</i> , 2020 , 158, 104898	10.2	26
121	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2704-2706	5.1	26
120	Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients. <i>Journal of Pharmaceutical Analysis</i> , 2016 , 6, 396-403	14	26
119	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016 , 8, 275-83	2.1	26
118	Therapeutic drug management of linezolid: a missed opportunity for clinicians?. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 728-731	14.3	25
117	Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 774, 187-94	3.2	25
116	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , 2005 , 18, 371-8	3	25
115	Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. <i>Pharmacological Research</i> , 2009 , 60, 221-8	10.2	24
114	Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 520-4	3.2	23
113	Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?. <i>PLoS ONE</i> , 2015 , 10, e0123670	3.7	22
112	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 83-92	3.2	21
111	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 86-92	3.1	19
110	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. <i>Kidney International</i> , 2004 , 65, 1084-90	9.9	19
109	Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019 , 44, 319-327	2.7	19
108	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 285-93	2.8	18
107	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , 2021 , 93, 1421-1427	19.7	17
106	Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1842-1844	5.1	16
105	Second generation antipsychotics in real-life paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1-8	4.1	16

104	Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 407-13	3.2	16
103	How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, e24-e26	3.1	15
102	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. <i>Clinica Chimica Acta</i> , 2005 , 355, 153-64	6.2	15
101	Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. <i>Clinical Biochemistry</i> , 2006 , 39, 1152-9	3.5	15
100	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 193-201	3.1	15
99	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, e403-4	3.4	14
98	Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 197-201	3.2	13
97	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020 , 4, 3648-3658	7.8	13
96	Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 440-5	2.9	12
95	Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. <i>Journal of Chromatographic Science</i> , 2008 , 46, 485-9	1.4	12
94	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. <i>Journal of Renal Nutrition</i> , 2005 , 15, 71-6	3	12
93	Cyclosporine formulation and Kaposi's sarcoma after renal transplantation. <i>Transplantation</i> , 2005 , 80, 743-8	1.8	12
92	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020 , 37, 925-933	4.7	12
91	Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. <i>American Journal of Nephrology</i> , 2007 , 27, 630-8	4.6	11
90	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 64-68	6.1	11
89	Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. <i>Aids</i> , 2017 , 31, 867-868	3.5	10
88	Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. <i>Frontiers in Pediatrics</i> , 2019 , 7, 309	3.4	10
87	Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2918-20	5.1	10

86	Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 927-935	5.5	10
85	Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. <i>Health Policy</i> , 2013 , 113, 216-20	3.2	10
84	Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. <i>Aids</i> , 2014 , 28, 2477-80	3.5	10
83	Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. <i>Pharmacological Research</i> , 2012 , 65, 163-7	10.2	10
82	Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?. <i>Antiviral Therapy</i> , 2017 , 22, 353-356	1.6	10
81	Dosing Colistin Properly: Let's Save "Our Last Resort Old Drug!". <i>Clinical Infectious Diseases</i> , 2017 , 65, 870	11.6	9
80	Clinical pharmacokinetics of ibuprofen arginine. <i>Current Clinical Pharmacology</i> , 2010 , 5, 239-45	2.5	9
79	Investigational drugs for diabetic nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1487-500	5.0	9
78	Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. <i>AIDS Reviews</i> , 2019 , 21, 40-49	1.5	8
77	Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 245-252	5.5	8
76	Prolonged inductive effect of rifampicin on linezolid exposure. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 643-4	2.8	8
75	Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study. <i>Clinical Drug Investigation</i> , 2015 , 35, 419-26	3.2	8
74	Are non-serious adverse reactions to psychiatric drugs really non-serious?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013 , 23, 394-400	2.9	8
73	Development of a CE method for the determination of mycophenolic acid in human plasma: a comparison with HPLC. <i>Electrophoresis</i> , 2007 , 28, 3908-14	3.6	8
72	Emerging drugs for diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , 2005 , 10, 747-71	3.7	8
71	Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?. <i>Aids</i> , 2018 , 32, 532-533	3.5	7
70	Orlistat: weight lost at cost of HIV rebound. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1739-41	5.1	7
69	Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 773-81	2.9	7

68	When food can make the difference: The case of elvitegravir-based co-formulation. <i>International Journal of Pharmaceutics</i> , 2016 , 512, 301-304	6.5	7
67	Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?. <i>Pharmacopsychiatry</i> , 2018 , 51, 270-271	2	7
66	Serotonin reuptake inhibitors in pregnancy: can genes help us in predicting neonatal adverse outcome?. <i>BioMed Research International</i> , 2014 , 2014, 276918	3	6
65	Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 739-45	3.2	6
64	Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 140-143	3.2	6
63	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 64-74	3.2	6
62	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 651-657	3.8	6
61	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109	6.2	6
60	Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 365-369	1.7	6
59	Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 441-445	3.2	5
58	How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2271-2273	5.1	5
57	Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?. <i>Obesity</i> , 2018 , 26, 1251-1252	4.252	5
56	Is it time to revise linezolid dose in elderly patients?. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1335-1336	2.8	5
55	Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 411-9	4.4	5
54	Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 341-8	1.7	5
53	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2004 , 14, 1553-1566	6.8	5
52	Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 1183-1192	5.5	5
51	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1341-5	5.1	4

50	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 545-9	14.3	4
49	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 95-105		4
48	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 559-572	2.7	3
47	Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 383-5	2.8	3
46	Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 34-45	3.8	3
45	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 365-7	2.8	3
44	Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 531-542	3.2	3
43	Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. <i>Fundamental and Clinical Pharmacology</i> , 2013 , 27, 216-22	3.1	3
42	Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?. <i>Clinical Infectious Diseases</i> , 2013 , 57, 480-1	11.6	3
41	Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. <i>Transplantation</i> , 2010 , 89, 126-7	1.8	3
40	LetQ assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications?. <i>Journal of Hepatology</i> , 2006 , 44, 837-8	13.4	3
39	Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 643-9	3.2	3
38	Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 330-334	3.2	3
37	Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. <i>International Journal of STD and AIDS</i> , 2020 , 31, 1008-1010	1.4	3
36	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016 , 47, 1287-8	13.6	3
35	Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1177-1178	2.8	2
34	Different effects of glucocorticoids on darunavir plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 733-735	2.8	2
33	Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 119-25	3.2	2

32	No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1467-1468	2.8	2
31	The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. <i>Antiviral Therapy</i> , 2018 , 23, 467-469	1.6	2
30	Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 204-6	3.1	2
29	Reply to Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients <i>Aids</i> , 2011 , 25, 1012-3; author reply 1011-2	3.5	2
28	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021 , 38, 341-346	4.7	2
27	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics Journal</i> , 2021 , 21, 586-593	3.5	2
26	Selective serotonin reuptake inhibitors passage into human milk of lactating women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019 , 32, 3020-3025	2	2
25	The management of anti-infective agents in intensive care units: the potential role of a fast Q pharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 355-366	3.8	2
24	Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1345-1350	6.2	1
23	Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. <i>Drugs in R and D</i> , 2020 , 20, 155-160	3.4	1
22	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1354-1356	5.1	1
21	Determinants of bone diseases in tenofovir-treated HIV patients. <i>Aids</i> , 2016 , 30, 1686-7	3.5	1
20	Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine. <i>CKJ: Clinical Kidney Journal</i> , 2012 , 5, 431-3	4.5	1
19	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. <i>Personalized Medicine</i> , 2004 , 1, 53-62	2.2	1
18	Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 999-1001	5.3	1
17	Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
16	Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 347-348	3.2	1
15	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study		1

14	Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, e17-e20	3.1	1
13	Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". <i>Clinical Pharmacokinetics</i> , 2021 , 60, 829-831	6.2	1
12	Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 285-7	3.2	1
11	Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 791-792	2.8	1
10	Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 603-609	6.2	1
9	In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 139, 111631	7.5	1
8	Effect of hepatitis B and C clearance on atazanavir exposure. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1409-11	2.8	0
7	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021 , 35, 2551-2553	3.5	0
6	Association of HIV Infection with Epilepsy and Other Comorbid Conditions. <i>AIDS and Behavior</i> , 2020 , 24, 1051-1055	4.3	0
5	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.. <i>Expert Review of Anti-Infective Therapy</i> , 2022 , 1-8	5.5	0
4	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. <i>Aids</i> , 2021 , 35, 522-524	3.5	
3	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 814-816	3.2	
2	Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples. <i>Journal of Chemotherapy</i> , 2021 , 1-10	2.3	
1	Doravirine/tenofovir disoproxil fumarate/lamivudine-induced alopecia: A case report.. <i>International Journal of STD and AIDS</i> , 2022 , 9564624221096299	1.4	